Study guide

12.4 Liquid Biopsy, ctDNA & Minimal Residual Disease

ASCP Molecular Biology Technologist MB

Track your progress as you read

Finished sections get a check mark.

1 Introduction & Exam Strategy

1.1 ASCP MB Exam Structure, Eligibility Routes & Policies 1.2 Computer Adaptive Testing (CAT) & Scoring Mechanics 1.3 Blueprint Navigation & Preparation Strategy

2 Nucleic Acid Chemistry & Molecular Structure

2.1 DNA Structure, Nitrogenous Bases & Thermodynamic Stability 2.2 RNA Types, Secondary Structure & Chemical Lability 2.3 Chromatin Organization, Histone Modifications & DNA Methylation

3 Central Dogma, Genome Organization & Cytogenetics

3.1 DNA Replication Machinery & Enzymology 3.2 Transcription, Translation & Genetic Code 3.3 Mutations, Polymorphisms & Chromosomal Aberrations

4 Biochemical Reagents & Enzymes

4.1 DNA Polymerases, Reverse Transcriptases & Proofreading 4.2 Restriction Endonucleases, Ligases & Nucleases 4.3 Reaction Buffers, Cations & Master Mix Additives

5 Nucleic Acid Isolation & Purification

5.1 Organic & Inorganic Extraction Chemistries 5.2 Solid-Phase Silica Columns & Magnetic Bead Isolation 5.3 Specimen-Specific Lysis & Challenging Matrices

6 Nucleic Acid Quantification & Electrophoresis

6.1 UV Spectrophotometry & Fluorometry 6.2 Agarose & Polyacrylamide Gel Electrophoresis 6.3 Capillary Electrophoresis & Microfluidic Bioanalyzers 6.4 Mass Spectrometry (MALDI-TOF) in Molecular Diagnostics

7 PCR Principles & Primer Design Optimization

7.1 Conventional PCR Thermodynamics & Cycling Kinetics 7.2 Primer Design Criteria, Melting Temp & Secondary Structures 7.3 PCR Inhibition, Facilitators & Troubleshooting

8 Advanced Amplification Technologies

8.1 Real-Time qPCR Probe Chemistries & Fluorescent Dyes 8.2 qPCR Quantification (Standard Curve, ΔΔCt) & Dissociation Melt Curve Analysis 8.3 Digital PCR (dPCR), Droplet Partitioning & Poisson Absolute Quantification 8.4 Isothermal & Target Multiplex Amplification

9 DNA Sequencing Technologies

9.1 Sanger Dideoxy Sequencing & Electropherogram Interpretation 9.2 NGS Library Preparation, Fragmentation & Target Enrichment 9.3 Massively Parallel NGS Platforms & Chemistries 9.4 NGS Quality Metrics, Coverage Depth & Bioinformatics

10 Hybridization, Blotting & Cytogenetic Assays

10.1 Southern, Northern & Dot Blot Chemistries 10.2 Fluorescence In Situ Hybridization (FISH) & CISH 10.3 Microarrays & Array Comparative Genomic Hybridization (aCGH)

11 Molecular Infectious Disease Diagnostics

11.1 Quantitative Viral Load Monitoring (HIV-1, HCV, HBV, CMV) 11.2 Qualitative Multiplex Syndromic Pathogen Panels 11.3 Antimicrobial Resistance Genotyping 11.4 Molecular Epidemiology & Pathogen Typing

12 Molecular Oncology & Hematopathology

12.1 Hematologic Malignancies & Translocation Assays 12.2 Solid Tumor Somatic Driver Mutations 12.3 Microsatellite Instability & DNA Mismatch Repair 12.4 Liquid Biopsy, ctDNA & Minimal Residual Disease

13 Medical Genetics, Pharmacogenomics & Identity Testing

13.1 Single-Gene Mendelian Disorders & CFTR Testing 13.2 Trinucleotide Repeat Expansion Disorders 13.3 Clinical Pharmacogenomics (PGx) Core Alleles 13.4 Human Identity Testing & Post-Transplant Chimerism

14 Quality Assurance, Controls & Method Validation

14.1 Quality Assurance Controls & Reference Materials 14.2 Clinical Method Validation & Performance Characteristics 14.3 Quality Management, Proficiency Testing & Competency

15 Laboratory Operations, Safety & Clinical Variant Reporting

15.1 Physical Facility Design & Unidirectional Workflow 15.2 Laboratory Biosafety, Chemical Hygiene & Waste 15.3 Clinical Calculations, ACMG Variant Classification & HGVS

12.4 Liquid Biopsy, ctDNA & Minimal Residual Disease

Key Takeaways Explain This Topic AI

Circulating cell-free DNA (cfDNA) consists of short double-stranded DNA fragments (~166 bp apoptotic nucleosomal units) released into plasma, with circulating tumor DNA (ctDNA) representing the tumor-derived subfraction (often shorter, ~130–150 bp).

cfDNA possesses an ultra-short biological half-life of 15 to 120 minutes, providing real-time dynamic monitoring of tumor burden, therapeutic efficacy, and molecular resistance mechanisms.

Pre-analytical integrity requires prompt plasma separation (two-step centrifugation: 1,600 x g then 16,000 x g) within 2–4 hours in EDTA, or collection in specialized preservative tubes (Streck, PAXgene) containing leukocyte stabilizers to prevent genomic DNA dilution from white blood cell lysis.

Ultra-sensitive detection relies on droplet digital PCR (ddPCR; LOD ~0.01–0.1% VAF) for known hotspot variants and hybrid-capture NGS with Unique Molecular Identifiers (UMIs) to computationally remove PCR duplication and sequencing artifacts.

Minimal / measurable residual disease (MRD) testing detects occult micro-metastatic disease post-resection or post-chemotherapy via tumor-informed (patient-specific custom panels) or tumor-naive approaches, predicting clinical relapse months prior to radiographic imaging.

Last updated: August 2026

12.4 Liquid Biopsy, ctDNA & Minimal Residual Disease

Quick Summary: Liquid biopsy analyzes circulating tumor-derived biomolecules—most prominently cell-free circulating tumor DNA (ctDNA) —isolated non-invasively from peripheral blood plasma. In contrast to tissue biopsies that are invasive and subject to spatial sampling bias, ctDNA captures comprehensive intra-tumoral and inter-metastatic clonal heterogeneity in real time. Because ctDNA fragments are short ( 130 – 150 base pairs ~130–150\text{ base pairs} 130–150 base pairs , derived from apoptotic nucleosomal cleavage) and clear rapidly from circulation ( half-life of 15 – 120 minutes 15–120\text{ minutes} 15–120 minutes ), liquid biopsy provides dynamic monitoring of disease burden. Ultra-sensitive analytical detection requires specialized pre-analytical preservation tubes, Droplet Digital PCR (ddPCR) , or hybrid-capture Next-Generation Sequencing (NGS) with Unique Molecular Identifiers (UMIs) to achieve limits of detection down to 0.01 % – 0.1 % 0.01\%–0.1\% 0.01%–0.1% Variant Allele Frequency (VAF) while filtering out biological confounders like Clonal Hematopoiesis of Indeterminate Potential (CHIP) .

1. Biophysical Characteristics & Fragmentomics of cfDNA and ctDNA

Cell-free DNA (cfDNA) consists of extracellular double-stranded DNA fragments circulating freely in blood plasma and bodily fluids. BIOPHYSICAL FRAGMENTOMICS OF cfDNA

  • [ Genomic Chromatin Structure ] [ Apoptotic Endonuclease Cleavage ]
  • Histone Octamer Core (147 bp) Caspase-Activated DNase (CAD) cleaves
  • + Linker DNA (~20 bp) = ~167 bp inter-nucleosomal linker DNA
  • /-----------------\ |
  • | (147 bp Core) | v
  • =====+===================+===== [ Mono-Nucleosomal Unit: ~166-167 bp ]
  • Linker DNA (~20 bp)
  • |
  • v
  • [ ctDNA Sub-Nucleosomal Fragment: ~130-150 bp ]
  • (Tumor DNA undergoes preferential end-trimming)

Apoptotic Origin & Size Distribution : cfDNA is released predominantly through physiologic apoptosis of normal hematopoietic cells. Apoptotic endonucleases (Caspase-Activated DNase, CAD) cleave accessible linker DNA between nucleosomes, generating a non-random fragment ladder with a prominent mono-nucleosomal peak at 166 – 167 base pairs ~166–167\text{ base pairs} 166–167 base pairs and smaller di-nucleosomal (~330 bp) and tri-nucleosomal (~500 bp) peaks.

ctDNA Fragment Shortening : Circulating tumor DNA fragments are systematically shorter than non-tumor cfDNA , exhibiting a characteristic peak between 130 and 150 base pairs 130\text{ and }150\text{ base pairs} 130 and 150 base pairs due to increased open chromatin accessibility and sub-nucleosomal end-trimming in malignant cells.

Ultra-Short Biological Half-Life : cfDNA has a circulating half-life of only 15 to 120 minutes 15\text{ to }120\text{ minutes} 15 to 120 minutes , cleared rapidly by hepatic Kupffer cells, the spleen, and renal excretion. Consequently, ctDNA represents a real-time "liquid snapshot" of active tumor turnover at the exact moment of phlebotomy.

2. Pre-Analytical Requirements & Artifact Prevention

Pre-analytical handling is the single most critical determinant of liquid biopsy analytical sensitivity. +----------------------------------------------------------------------------------------------------+

  • | LIQUID BIOPSY PRE-ANALYTICAL SPECIMEN REQUIREMENTS |
  • +-------------------+-------------------+-------------------+----------------------------------------+
  • | Parameter | Standard K2-EDTA | Specialized cfDNA | Critical Operational Pitfalls & QC |
  • | | Phlebotomy Tubes | Preservative Tubes| Rules |
  • +-------------------+-------------------+-------------------+----------------------------------------+
  • | **Blood Tube Type**| Standard lavender-| Streck Cell-Free | Specialized tubes contain chemical |
  • | | top K2-EDTA tube | DNA BCT, PAXgene, | fixatives that stabilize leukocyte |
  • | | (no fixative) | Roche cfDNA tube | membranes without cell lysis |
  • +-------------------+-------------------+-------------------+----------------------------------------+
  • | **Processing Time | **Within 2 to 4 | **Stable 7 to 14 | Delayed EDTA processing causes WBC |
  • | Window** | hours maximum** | days at room temp | lysis, releasing massive genomic DNA |
  • | | at room temp | (15°C to 30°C)** | that fatally dilutes rare ctDNA |
  • +-------------------+-------------------+-------------------+----------------------------------------+
  • | **Centrifugation | **Two-Step Spin**:| **Two-Step Spin**:| 1st Spin: Pellets intact cells (WBCs/RBCs)|
  • | Protocol** | 1) 1,600 x g (10m)| 1) 1,600 x g (10m)| 2nd Spin: Pellets platelets & debris; |
  • | | 2) 16,000 x g(10m)| 2) 16,000 x g(10m)| prevents platelet lysis during freeze |
  • +-------------------+-------------------+-------------------+----------------------------------------+
  • | **Storage & Temp | Store plasma at | Store whole blood | **NEVER FREEZE WHOLE BLOOD!** Freezing |
  • | Precautions** | **-80°C**; do not | at **15°C–30°C**; | causes ice crystal rupture of WBCs; |
  • | | freeze whole blood| do not refrigerate| do not refrigerate preservative tubes |

+-------------------+-------------------+-------------------+----------------------------------------+ THE GENOMIC DNA DILUTION EFFECT

  • [ Properly Processed EDTA (<2 hr) ] [ Delayed EDTA Processing (>6 hr) ]
  • Intact WBCs removed -> High VAF WBCs lyse -> Flood of Genomic DNA (>10 kb)
  • ctDNA Copies: 50 ctDNA Copies: 50
  • Normal cfDNA: 4,950 Normal DNA: 99,950 (Massive WBC lysis!)
  • Total DNA: 5,000 copies Total DNA: 100,000 copies
  • ------------------------------- --------------------------------
  • Variant VAF: 1.0% (DETECTABLE!) Variant VAF: 0.05% (BELOW LOD -> FALSE NEG!)
  • 3. Biological Confounders: Clonal Hematopoiesis of Indeterminate Potential (CHIP)

A major biological challenge in liquid biopsy interpretation is Clonal Hematopoiesis of Indeterminate Potential (CHIP) . CLONAL HEMATOPOIESIS (CHIP) IN LIQUID BIOPSY

  • [ Bone Marrow Hematopoietic Stem Cell (HSPC) ]
  • |
  • Acquires Age-Related Somatic Mutation (DNMT3A, TET2, ASXL1, TP53)
  • |
  • v
  • [ Clonal White Blood Cell Pool ]
  • |
  • Apoptosis & Normal Turnover
  • |
  • v
  • [ Mutated DNA Shed into Plasma Cell-Free DNA Pool ]
  • |
  • *** DANGER: False Positive Classification as Solid Tumor Driver! ***
  • *** SOLUTION: Paired Sequencing of Matched White Blood Cell Buffy Coat ***

Etiology : With advancing age, hematopoietic stem cells acquire somatic mutations in epigenetic regulators and tumor suppressors—most frequently DNMT3A , TET2 , ASXL1 , TP53 , PPM1D , and JAK2 —expanding into distinct leukocyte clones without causing overt hematologic malignancy.

Diagnostic Confounder : Circulating CHIP leukocytes undergo apoptosis and shed mutated cfDNA into plasma at variant allele frequencies ranging from 0.1 % 0.1\% 0.1% to > 5 % >5\% > 5% . Without proper controls, these mutations are easily misidentified as solid tumor somatic driver mutations, risking incorrect cancer diagnoses or inappropriate targeted therapies.

Laboratory Resolution : Comprehensive liquid biopsy panels perform paired sequencing of the leukocyte cellular pellet (buffy coat genomic DNA) alongside plasma cfDNA. Variants detected concurrently in both plasma and buffy coat at equivalent allele fractions are flagged as CHIP-derived and computationally filtered out.

4. Ultra-Sensitive Detection Technologies: ddPCR & UMI-NGS

Detecting rare ctDNA molecules present at variant allele frequencies of < 0.1 % <0.1\% < 0.1% requires specialized error-suppressed technologies. +----------------------------------------------------------------------------------------------------+

  • | ULTRA-SENSITIVE ctDNA DETECTION METHODOLOGIES |
  • +-------------------+-------------------+-------------------+----------------------------------------+
  • | Technology | Limit of Detection| Target Breadth | Molecular Mechanism & Error Control |
  • +-------------------+-------------------+-------------------+----------------------------------------+
  • | **Droplet Digital | **~0.01%–0.1% | Single targeted | Water-in-oil partitioning into 20,000 |
  • | PCR (ddPCR)** | VAF** | mutation per assay| nanoliter droplets; single-molecule |
  • | | | (e.g., EGFR T790M)| Poisson statistical quantification |
  • +-------------------+-------------------+-------------------+----------------------------------------+
  • | **Targeted Hybrid-| **~0.1%–0.5% | Multi-gene panel | Solution hybridization capture; |
  • | Capture NGS** | VAF** | (50–500 genes) | deep coverage (10,000x raw depth) |
  • +-------------------+-------------------+-------------------+----------------------------------------+
  • | **UMI-Barcoded | **~0.01%–0.05% | Targeted broad | Unique Molecular Identifiers (UMIs) |
  • | Duplex NGS** | VAF** | panels & exomes | tag individual double-stranded templates|
  • | | | | to computationally remove PCR errors |
  • +-------------------+-------------------+-------------------+----------------------------------------+
  • Unique Molecular Identifiers (UMIs) & Computational Error Suppression

In standard NGS, Taq polymerase incorporation errors ( 10 − 3 ~10^{-3} 1 0 − 3 to 10 − 4 10^{-4} 1 0 − 4 per base) and sequencing platform noise create background false-positive rates that obscure low-frequency ctDNA mutations ( < 0.5 % <0.5\% < 0.5% VAF). UNIQUE MOLECULAR IDENTIFIERS (UMI) WORKFLOW

  • Step 1: Tagging Original Templates with Degenerate UMI Barcodes
  • Template Molecule A: [ UMI-1 (ATCG) ]==== DNA Insert ====[ UMI-1 (ATCG) ]
  • Template Molecule B: [ UMI-2 (GGTA) ]==== DNA Insert ====[ UMI-2 (GGTA) ]
  • Step 2: Library Amplification (PCR Introduces Sporadic Polymerase Errors)
  • UMI-1 Copies: [ UMI-1 ]==== [ True Mutation: G>A ] ====[ UMI-1 ] (All Copies!)
  • [ UMI-1 ]==== [ True Mutation: G>A ] ====[ UMI-1 ]
  • [ UMI-1 ]==== [ True Mutation: G>A ] ====[ UMI-1 ]
  • UMI-2 Copies: [ UMI-2 ]==== [ Wild-Type Target ] ====[ UMI-2 ]
  • [ UMI-2 ]==== [ PCR Error: C>T ] ====[ UMI-2 ] (Only 1 Copy!)
  • [ UMI-2 ]==== [ Wild-Type Target ] ====[ UMI-2 ]
  • Step 3: Bioinformatic Consensus Building (Error Collapsing)
  • UMI-1 Consensus: TRUE SOMATIC MUTATION (Present in 100% of UMI-1 Family Reads) -> KEPT

UMI-2 Consensus: WILD-TYPE (C>T error present in only 1 read of family) -> DISCARDED AS ARTIFACT!

5. Clinical Applications: Minimal Residual Disease (MRD) & Resistance Tracking +----------------------------------------------------------------------------------------------------+

  • | CLINICAL PARADIGMS OF LIQUID BIOPSY TESTING |
  • +-------------------+-------------------+-------------------+----------------------------------------+
  • | Clinical Utility | Biomarker Targets | Clinical Setting | Diagnostic & Therapeutic Impact |
  • +-------------------+-------------------+-------------------+----------------------------------------+
  • | **Therapy | *EGFR* T790M, | Advanced metastatic| Non-invasive genotyping when tissue |
  • | Selection** | *KRAS*, *BRAF*, | solid tumors | biopsy is inaccessible, insufficient, |
  • | | *PIK3CA*, *ESR1* | (NSCLC, CRC, Breast)| or high-risk for complications |
  • +-------------------+-------------------+-------------------+----------------------------------------+
  • | **Minimal Residual| Patient-specific | Post-curative | Detects microscopic residual disease; |
  • | Disease (MRD)** | clonal variants | surgical resection| predicts clinical relapse **3 to 9 |
  • | | (Tumor-informed) | or chemotherapy | months earlier** than radiographic CT |
  • +-------------------+-------------------+-------------------+----------------------------------------+
  • | **Acquired | *EGFR* C797S, | Longitudinal | Detects emerging subclonal resistance |
  • | Resistance** | *ESR1* Y537S/D538G| serial monitoring | mutations weeks to months prior to |
  • | | *AR* T878A, *KRAS*| during therapy | overt symptomatic disease progression |
  • +-------------------+-------------------+-------------------+----------------------------------------+
  • Tumor-Informed vs. Tumor-Naive MRD Assays

Tumor-Informed Assay (e.g., Signatera) : Whole-exome sequencing of the patient's surgically resected primary tumor is performed to identify 16 to 30 patient-specific clonal somatic single nucleotide variants . A bespoke, custom multiplex PCR/NGS panel is then synthesized exclusively for that individual patient to track ctDNA in serial plasma blood draws. Achieves maximum analytical sensitivity ( LOD down to 0.001 % – 0.01 % 0.001\%–0.01\% 0.001%–0.01% VAF ).

Tumor-Naive / Tumor-Agnostic Assay (e.g., Guardant Reveal) : Evaluates plasma using a fixed panel targeting recurrent genomic mutations combined with cancer-specific aberrant DNA methylation signatures. Does not require surgical tissue; provides faster turnaround time but lower personalized depth.

Loading diagram... Liquid Biopsy Pre-Analytical, Analytical, and Bioinformatic Pipeline